Cholestasis ameliorant

• US 5,863,550 A
• Filed: 12/01/1995
• Issued: 01/26/1999
• Est. Priority Date: 03/31/1993
• Status: Expired due to Fees

• Current Assignee: TT Pharmaceuticals Incorporated
• Original Assignee: Tokyo Tanabe Company, Ltd.
• Inventors: Koiso, Kumiko, Sekido, Shozaburo, Maeda, Minoru
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US08/530,151
• Time in Patent Office: 1,152 Days
• Field of Search: 424/423, 424/451, 424/464, 514/182
• US Class Current: 424/423
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: C07J 41/0061 one of the carbon atoms being part of an amide group

Abstract

Disclosed is a cholestasis ameliorant containing tauroursodeoxycholic acid, which is more excellent in solubility than ursodeoxycholic acid, as the active ingredient. The ameliorant is useful for the treatment of intrahepatic cholestasis due to drug-induced hepatopathy, viral hepatitis or the like and the treatment of cholestasis occurring after surgical operation for the treatment of obstructive jaundice.

Claims

1. A cholestasis ameliorant with an active ingredient consisting of tauroursodeoxycholic acid, wherein said acid is prepared in purified water or physiological saline for injection.

2. A cholestasis ameliorant according to claim 1, wherein the active ingredient is contained at a concentration of 1 to 10% (W/V) in an aqueous solution suitable for injection.

3. A cholestasis ameliorant with an active ingredient consisting of tauroursodeoxycholic acid, in a pharmaceutical preparation suitable for oral administration.

4. A method for the treatment of cholestasis comprising the administration via injection of an effective amount of a composition comprising tauroursodeoxycholic acid in a pharmaceutically acceptable aqueous composition.

5. The method of claim 4 wherein the tauroursodeoxycholic acid is contained at a concentration of 1 to 10% (W/V).

6. A method for the treatment of cholestasis comprising the oral administration of an effective amount of a composition comprising tauroursodeoxycholic acid in a pharmaceutically acceptable composition.